Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a late-stage biopharmaceutical company devoted to addressing chronic pruritic conditions and chronic cough through its investigational therapy, Haduvio™ (oral nalbuphine ER). Haduvio is an oral extended-release formulation of nalbuphine, a synthetic opioid with a dual mechanism of action: as a ĸ-opioid receptor agonist and µ-opioid receptor antagonist. This unique mechanism has shown promise in clinical trials for reducing symptoms associated with chronic cough, particularly in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis, a dermatologic condition characterized by pruriginous lesions.
Trevi is advancing various pruritic conditions through clinical development, including prurigo nodularis, which currently has no approved therapies in the US or EU. The company's lead indication involves extensive studies and trials, such as the recent Phase 2b/3 PRISM (Pruritus Relief through Itch-Scratch Modulation) trial, which demonstrated Haduvio's efficacy and safety over 52 weeks.
In the chronic cough segment, Trevi's Haduvio is undergoing trials like the Phase 2a RIVER study for RCC and the Phase 2b CORAL trial for chronic cough in IPF. The RIVER trial is a double-blind, placebo-controlled study evaluating Haduvio's impact on 24-hour cough frequency, while the CORAL trial investigates three dose levels of Haduvio against a placebo in IPF patients, assessing endpoints like cough frequency reduction and quality of life improvements.
Trevi's innovative approach aims to provide relief where current treatments fail, supported by promising clinical data and ongoing trials. The company's commitment to addressing unmet medical needs is reflected in its thorough and transparent communication with investors and stakeholders, ensuring that all developments are promptly shared, including financial results and future plans.
For more detailed information on Trevi Therapeutics, its clinical trials, and its forward-looking statements, visit TreviTherapeutics.com and follow the company on Twitter and LinkedIn.
Trevi Therapeutics (Nasdaq: TRVI) announced that additional analyses of cough relief time from their Phase 2a CANAL trial have been accepted for oral presentation at CHEST 2024. The presentation, by Professor Alyn Morice, will cover post-hoc analyses of 38 IPF patients who completed at least one treatment period. Results showed:
1. Significant increase in relief-of-cough time
2. Reduced cough time
3. Reduced cough intensity
These effects were observed in IPF patients treated with nalbuphine ER compared to placebo. The safety profile was consistent with previous trials. Common adverse events included nausea, dizziness, and anxiety. The presentation is scheduled for October 8, 2024, at the CHEST Annual Meeting in Boston.
Trevi Therapeutics (Nasdaq: TRVI) announced that data from their Phase 2a CANAL trial on Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) Congress 2024 in Vienna, Austria. The presentation, scheduled for September 8th, will focus on the correlation between changes in objective cough count and improvements in patient-reported outcomes with nalbuphine ER in IPF patients. Professor Jacky Smith, a renowned respiratory medicine expert, will deliver the oral presentation, highlighting the importance of patient-reported outcomes in clinical trials for chronic cough treatments, which remain a significant unmet need for IPF patients.
Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing Haduvio™ for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), announced its participation in several investor and medical conferences in September 2024. These include:
- 2024 Wells Fargo Healthcare Conference (Sept 4-6, Boston)
- European Respiratory Society Congress 2024 (Sept 7-11, Vienna)
- H.C. Wainwright 26th Annual Global Investment Conference (Sept 9-11, New York)
- 2024 Cantor Global Healthcare Conference (Sept 17-19, New York)
Senior management, including CEO Jennifer Good and CFO Lisa Delfini, will represent Trevi at these events. Corporate presentations are scheduled at the H.C. Wainwright and Cantor conferences, with the latter being available for public viewing via registration.
Trevi Therapeutics reported its second quarter 2024 financial results and provided business updates. The company is developing the investigational therapy Haduvio™ for chronic cough in IPF and RCC. Key updates include:
1. RIVER Trial: Phase 2a trial in RCC is 80% enrolled with topline data expected in Q4 2024.
2. CORAL Trial: Phase 2b trial in IPF chronic cough with sample size re-estimation milestone in Q4 2024.
3. Financials: Ended the quarter with $69.5 million in cash and expected runway into 2026. R&D expenses increased to $10.0 million, G&A expenses to $3.3 million, leading to a net loss of $12.4 million.
4. Other studies include the HAP study and the TIDAL respiratory physiology study.
Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, has announced it will report its second quarter 2024 financial results and provide a corporate update on August 8, 2024. The company is developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). A conference call and live audio webcast will be held at 4:30 p.m. ET on the same day.
Interested parties can join the call by dialing (877) 870 4263 (domestic) or (412) 317 0790 (international) and asking to join the Trevi Therapeutics call. A live audio webcast will be available on the company's website, with an archived replay accessible for 30 days following the event.
Trevi Therapeutics (Nasdaq: TRVI), specializing in therapies for chronic cough, announced their participation in key investor and healthcare events in July and August 2024. Senior management, including CEO Jennifer Good and CFO Lisa Delfini, will represent the company at the Leerink Partners Therapeutics Forum on July 9-10 in Boston, MA. Additionally, two abstracts from Trevi's ongoing clinical trials, CORAL (Phase 2b) and RIVER (Phase 2a), have been accepted for presentation at the 13th London International Cough Symposium on July 18-19, 2024. The symposium will discuss advancements in chronic cough research and treatment. CEO Jennifer Good will also represent Trevi at Oppenheimer's Biotech in the Berkshires on August 5-7 in Lenox, MA, and the Stifel 2024 Biotech Summer Summit on August 12-14 in Newport, RI.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company (Nasdaq: TRVI), will participate in upcoming investor, business development, and medical conferences in May and June. The company is focused on developing Haduvio™ for chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough. Senior management will attend various events, including the Citizens JMP Life Sciences Conference, ATS 2024 International Conference, 2024 BIO International Convention, and Oppenheimer's 2024 Montauk Life Sciences Summit.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) reported Q1 2024 financial results and business updates, reaffirming guidance for Phase 2a RIVER trial and HAP Study. Topline data for both trials expected in 2024. IND cleared for Phase 1b trial. Key business updates include progress in clinical trials, with Phase 2a RIVER trial and Phase 2b CORAL trial enrollment ongoing. The company ended Q1 2024 with $72.8 million in cash. Financially, R&D expenses increased to $8.8 million, G&A expenses were $3.1 million, with a net loss of $10.9 million. Conference call/webcast and upcoming meetings announced for investor participation.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will host a conference call and webcast on May 7, 2024, to discuss the corporate update and financial results for the first quarter of 2024. The company is developing Haduvio™ for chronic cough in IPF and RCC. Investors can participate via phone or webcast.
FAQ
What is the current stock price of Trevi Therapeutics (TRVI)?
What is the market cap of Trevi Therapeutics (TRVI)?
What is Trevi Therapeutics, Inc.?
What is Haduvio?
What are the primary conditions Trevi Therapeutics is targeting?
What are the latest clinical trials conducted by Trevi Therapeutics?
Has Haduvio been proven effective?
Are there any approved therapies for the conditions Trevi Therapeutics is addressing?
What are the next steps for Trevi Therapeutics in their clinical trials?
Where can investors find more information about Trevi Therapeutics?
What financial results were reported by Trevi Therapeutics in the latest quarter?
How does Trevi Therapeutics ensure communication with its stakeholders?
